Get the Stockscreener App
31.50
3.76%
1.145
Veracyte Inc stock is traded at $31.50, with a volume of 577.35K.
It is up +3.76% in the last 24 hours and up +8.77% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
See More
Previous Close:
$30.35
Open:
$30.48
24h Volume:
577.35K
Relative Volume:
0.61
Market Cap:
$2.48B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-41.99
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
-0.57%
1M Performance:
+8.77%
6M Performance:
-12.36%
1Y Performance:
+54.74%
1-Day Range:
$30.45
$31.59
1-Week Range:
$29.30
$31.89
52-Week Range:
$19.73
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
31.50 | 2.48B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
423.25 | 159.05B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
198.50 | 140.21B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
481.77 | 35.17B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
108.71 | 30.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.10 | 26.47B | 15.41B | 1.37B | 2.11B | 7.50 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Breaking Down the Benefits of Clinical Trial Participation in Cancer Care - Curetoday
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer - BioSpace
Veracyte launches prostate metastatic test - MSN
Crafting an Individual Treatment Plan for Patients With Prostate Cancer - Curetoday
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms - Benzinga
Veracyte launches metastatic prostate cancer test - Investing.com
Veracyte launches metastatic prostate cancer test By Investing.com - Investing.com South Africa
Veracyte launches prostate metastatic test (VCYT:NASDAQ) - Seeking Alpha
Veracyte (VCYT) Boosts Cancer Care with New Genomic Classifier L - GuruFocus
Veracyte Announces Expanded Availability of Decipher Prostate Te - GuruFocus
Veracyte Announces Expanded Availability Of Decipher Prostate Test To Patients With Metastatic Prostate Cancer - marketscreener.com
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer | VCYT Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Veracyte Announces Multiple Abstracts Demonstrating Power of Dec - GuruFocus
Breakthrough Cancer Insights: 18 New Studies Confirm Veracyte Decipher Test's Power in Prostate and Bladder Cancer - Stock Titan
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release - 01net
Veracyte data joins NCI SEER database for research By Investing.com - Investing.com South Africa
Veracyte Announces Decipher Prostate Genomic Classifier Results - GuruFocus
Veracyte data joins NCI SEER database for research - Investing.com
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release | VCYT Stock News - GuruFocus
Should You Continue to Hold Veracyte Stock in Your Portfolio? - MSN
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 - 01net
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 | VCYT Stock News - GuruFocus
Cancer Diagnostics Leader Veracyte Announces Q1 2025 Earnings Date: Key Updates Coming May 7 - Stock Titan
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Here's Why Veracyte (VCYT) is a Strong Growth Stock - Yahoo Finance
Veracyte And 2 More Stocks That Might Be Trading Below Their Estimated Value - Yahoo Finance
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago - MSN
Veracyte (VCYT) Just Overtook the 20-Day Moving Average - Yahoo Finance
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength? - Nasdaq
Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating By Investing.com - Investing.com South Africa
Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating - Investing.com Australia
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Veracyte Scores Relative Strength Rating Upgrade; Hits Key Threshold - MSN
Veracyte (VCYT) Introduces AI-Powered Cancer Detection – Faster and More Accurate Than Ever! - Insider Monkey
9 AI News and Ratings on Investors’ Radar - Insider Monkey
Craig-Hallum bullish on Veracyte, initiates with a Buy - MSN
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade - Yahoo
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer - 01net
Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests - MarketScreener
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.16%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):